SINOTHERAPEUTICS

Zhitong · Oct 30, 2025 at 03:33 AM

SINOTHERAPEUTICS released its performance for the first three quarters, with a net profit attributable to the parent company of 63.46 million yuan, a year-on-year decrease of 31.45%

Zhitong · Oct 29, 2025 at 02:34 AM

SINOTHERAPEUTICS: The company's products are expected to be selected for the national centralized procurement of drugs

Zhitong · Oct 20, 2025 at 03:21 AM

SINOTHERAPEUTICS: The Sitagliptin Metformin Extended-Release Tablets have received approval from the U.S. FDA

Zhitong · Sep 30, 2025 at 05:02 AM

Wu Huafeng, Deputy General Manager of Shanghai SINOTHERAPEUTICS, has resigned early for personal reasons

Zhitong · Sep 26, 2025 at 03:06 AM

SINOTHERAPEUTICS: New specifications for Sitagliptin Metformin Extended-Release Tablets approved

Zhitong · Aug 24, 2025 at 08:01 PM

Zhitong A-share lock-up release overview | August 25